In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China.
The antibiotic susceptibilities of seven Borrelia burgdorferi sensu lato isolates from Ixodes persulcatus in China were examined by in-vitro microdilution minimum inhibition concentration (MIC) and macrodilution minimum bactericidal concentration (MBC) methods. All isolates tested were susceptible to amoxicillin, erythromycin, and minocycline. The MICs of these drugs for the Chinese isolates were 0.025-0.1 microg/ml, <0.012-0.05 microg/ml, and <0.012-0.05 microg/ml, respectively. The MBCs were 0.1-0.39 microg/ml, <0.012-0.2 microg/ml, and 0.025-0.39 microg/ml, respectively. The in-vivo antimicrobial susceptibilities of the Chinese Borrelia isolates to two test drugs, amoxicillin and minocycline, were evaluated using ddY mice. Mice were infected by subcutaneous inoculation into the right hind footpad. When infection was confirmed, the mice were treated by subcutaneous injection of the test drugs into the back. Amoxicillin and minocycline, which possessed high in-vitro activities against Lyme disease Borrelia, provided good protection against borreliosis in this animal model. Higher doses of these drugs resulted in elimination of the Lyme disease spirochete from all animals receiving this course of treatment. The 50% curative doses (CD50) of amoxicillin and minocycline were 8.7 mg/kg and 3.1 mg/kg, respectively. This suggested that amoxicillin and minocycline could be useful for the treatment of Chinese Borrelia infection.
Li
M
M
International Center for Medical Research, Kobe University School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650, Japan. muqingl@kobe-u.ac.jp
Masuzawa
T
T
Wang
J
J
Kawabata
M
M
Yanagihara
Y
Y
D000658:Amoxicillin / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D025065:Borrelia burgdorferi / Q000187:drug effects* / Q000302:isolation & purification; D002506:Cephalexin / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology; D002681:China; D004917:Erythromycin / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008193:Lyme Disease / Q000188:drug therapy*; D051379:Mice; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000494:pharmacology*; D010406:Penicillins / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D004917:Erythromycin; D000658:Amoxicillin; D008911:Minocycline; D002506:Cephalexin